Forging ahead – Advances in generic drug development in the USA
By Dr Nicola Davies
In 2022, 91% of prescriptions in the USA were filled by generic drugs, which in turn accounted for only 18.2% of the country’s pharmaceutical spending.1
The average co-pay for a brand-name drug was about nine times higher at $56.12 than that for a generic drug at $6.16.1 The overall generics market in the USA was estimated at $435.54 billion in 2022, with a projection to reach $721.54 billion by 2032.2 The top 10 generics of 2021 helped the USA healthcare system save $110 billion.1 It is evident that generics have been pivotal in improving access to medication in the USA while reducing costs and healthcare spending without compromising quality of care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze